Silexion Completes Key Preclinical Studies for SIL204

Silexion Therapeutics ( (SLXN) ) has issued an update.

On May 21, 2025, Silexion Therapeutics announced the completion of key preclinical studies for its RNAi therapeutic candidate, SIL204, targeting colorectal and lung cancer applications. These studies, which also included pancreatic cancer, mark a significant milestone in Silexion’s development program, potentially expanding its strategy to address unmet needs in KRAS-driven tumors, a market valued at over $30 billion annually.

The most recent analyst rating on (SLXN) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.

Spark’s Take on SLXN Stock

According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.

Silexion Therapeutics has significant financial difficulties with zero revenue and negative equity, posing major risks. Technical analysis indicates a bearish trend, and speculative valuation metrics reflect the high-risk nature of the stock. However, promising corporate developments, such as the SIL204 partnership and positive preclinical results, offer potential upside if clinical success is achieved.

To see Spark’s full report on SLXN stock, click here.

More about Silexion Therapeutics

Silexion Therapeutics is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapies for KRAS-driven cancers. The company is pioneering oncology treatments with its innovative RNAi-based strategies, including its first-generation product LODER™, which has shown promise in Phase 2 trials for pancreatic cancer, and its next-generation candidate SIL204.

Average Trading Volume: 4,508,265

Technical Sentiment Signal: Sell

Current Market Cap: $8.11M

See more insights into SLXN stock on TipRanks’ Stock Analysis page.